CL2024000593A1 - Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento... - Google Patents

Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento...

Info

Publication number
CL2024000593A1
CL2024000593A1 CL2024000593A CL2024000593A CL2024000593A1 CL 2024000593 A1 CL2024000593 A1 CL 2024000593A1 CL 2024000593 A CL2024000593 A CL 2024000593A CL 2024000593 A CL2024000593 A CL 2024000593A CL 2024000593 A1 CL2024000593 A1 CL 2024000593A1
Authority
CL
Chile
Prior art keywords
preparation
treatment
drugs
ezh2 inhibitor
drug
Prior art date
Application number
CL2024000593A
Other languages
English (en)
Inventor
Zhang Xiaojing
Wang Weiwei
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of CL2024000593A1 publication Critical patent/CL2024000593A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso de un inhibidor de EZH2 en la preparación de un fármaco para el tratamiento de linfoma de linfocitos T. Específicamente, la presente invención se refiere al uso de un compuesto según se representa en la fórmula (I) o una sal farmacéuticamente aceptable del mismo en la preparación de un fármaco para el tratamiento de linfoma de linfocitos T.
CL2024000593A 2021-08-30 2024-02-27 Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento... CL2024000593A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111001663 2021-08-30

Publications (1)

Publication Number Publication Date
CL2024000593A1 true CL2024000593A1 (es) 2024-07-05

Family

ID=85411942

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024000593A CL2024000593A1 (es) 2021-08-30 2024-02-27 Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento...

Country Status (16)

Country Link
US (1) US20240325371A1 (es)
EP (1) EP4393490A4 (es)
JP (1) JP2024530310A (es)
KR (1) KR20240056564A (es)
CN (1) CN117956995A (es)
AU (1) AU2022340500A1 (es)
CA (1) CA3230149A1 (es)
CL (1) CL2024000593A1 (es)
CO (1) CO2024003923A2 (es)
CR (1) CR20240147A (es)
IL (1) IL311097A (es)
MA (1) MA65131B1 (es)
MX (1) MX2024002538A (es)
PE (1) PE20240881A1 (es)
TW (1) TW202327597A (es)
WO (1) WO2023030299A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
PE20150887A1 (es) * 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
RS59763B1 (sr) 2015-11-19 2020-02-28 Jiangsu Hengrui Medicine Co Derivati benzofurana, postupci njihove pripreme i njihova upotreba u medicini
CN108314677B (zh) * 2017-01-17 2020-06-30 安徽中科拓苒药物科学研究有限公司 一种ezh2抑制剂及其用途
EP3626715A4 (en) * 2017-05-18 2021-03-24 Jiangsu Hengrui Medicine Co., Ltd. CRYSTAL OF A BENZOFURAND DERIVATIVE-FREE BASE AND MANUFACTURING PROCESS
CN110179796B (zh) * 2018-02-23 2023-01-24 江苏恒瑞医药股份有限公司 一种苯并呋喃类衍生物的组合物及制备方法
WO2020192652A1 (zh) * 2019-03-25 2020-10-01 上海华汇拓医药科技有限公司 酰胺类化合物制备方法及其在医药领域的应用
WO2020228591A1 (zh) * 2019-05-10 2020-11-19 江苏恒瑞医药股份有限公司 一种6-取代氨基苯并呋喃化合物的制备方法
WO2021063340A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂、酪氨酸激酶抑制剂联合在制备治疗肿瘤药物中的用途
WO2021063331A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途

Also Published As

Publication number Publication date
JP2024530310A (ja) 2024-08-16
CN117956995A (zh) 2024-04-30
WO2023030299A1 (zh) 2023-03-09
IL311097A (en) 2024-04-01
KR20240056564A (ko) 2024-04-30
CR20240147A (es) 2024-09-20
MA65131B1 (fr) 2025-05-30
TW202327597A (zh) 2023-07-16
MX2024002538A (es) 2024-03-19
US20240325371A1 (en) 2024-10-03
PE20240881A1 (es) 2024-04-24
AU2022340500A1 (en) 2024-04-11
MA65131A1 (fr) 2024-11-29
CA3230149A1 (en) 2023-03-09
EP4393490A1 (en) 2024-07-03
CO2024003923A2 (es) 2024-06-27
EP4393490A4 (en) 2025-08-27

Similar Documents

Publication Publication Date Title
CL2024000593A1 (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento...
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
DOP2019000201A (es) Compuestos inhibidores del vih
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
PE20160180A1 (es) Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos.
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
ECSP22032016A (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
CL2022002817A1 (es) Inhibidores de replicación del virus de inmunodeficiencia humana
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
CL2025000529A1 (es) Compuestos derivados de dioxoisoquinolinona, inhibidores de ezh1 y/o ezh2; uso para tratar cáncer.
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
AR127165A1 (es) Resmetirom para reducir el volumen del hígado
CL2024001073A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
MX2024001613A (es) Derivado de oxaspiro, metodo de preparacion del mismo y uso del mismo.
CL2024001524A1 (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
AR131842A1 (es) Métodos para tratar gliomas
CO2022004768A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
MX2024014557A (es) Derivados de piperazina útiles en la terapia contra el vih
CO2023004589A2 (es) Compuestos y métodos para el tratamiento de infecciones por virus